News sentiment analysis powered by sentiment-insight.com
GSK says blood cancer drug meets primary goal in...
British drugmaker GSK said its blood cancer drug Blenrep met its primary goal of progression-free survival in a late-stage trial. In September, EU's drug regulator recommended against renewing the conditional marketing authorisation for the drug.
BUSINESS LIVE: Rio Tinto agrees SEC settlement; Kingfisher slashes profit outlook; Sage Group lifts... GSK plans low-carbon asthma inhaler in bid to cut emissions. Sage expects its profit margin to continue to increase this year.
GSK plans low-carbon asthma inhaler in bid to cut its greenhouse gas emissions GSK is planning to create a low-emission version of its Ventolin medicine. Its Ventolin inhalers account for nearly half its total greenhouse gas output. The inhaler’s propellant is a key source of emissions.
Investors should sit back, relax and enjoy further gains from Haleon Despite a share price rise of 9pc since our initial recommendation in December last year, we think the consumer healthcare business Haleon is worth sticking with. The company sells well known brands such as Sensodyne, Panadol and Voltaren and was once part of drugs giant GSK.
GSK Buy Write Is Prescription For Quick Dividend If we earn the dividend and if GSK closes above $35 at expiration on December 22, we will be assigned and compelled to sell our shares at $35. This would produce a total return of $1.41 per share on $34.95 per share at risk, or 4.03%.
After A Banner Week On Wall Street, Is A Recession On The Way? Last week was the best week for the markets in 2023. Companies added more than $1 trillion in collective market value. Drugmaker GSK saw its sales increase 10% in the quarter.
Advil maker Haleon misses revenue estimates as North... Advil maker Haleon misses revenue estimates as North America demand drags. Haleon makes painkillers such as Advil and Panadol, as well as Sensodyne toothpaste. The company was carved out of British drugmaker GSK last year.
Reuters Health News Summary GE HealthCare beats quarterly profit estimates on imaging device demand. GSK to pay $1 billion for exclusive license to J&J's hepatitis B therapy. FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study.
InnovationRx: The VA’s Call For AI Tools The U.S. Department of Veterans Affairs has issued a call for two different types of health-related artificial intelligence tools. Covera Health, a startup using AI to improve the accuracy of radiology imaging, said it has raised $25 million. 23andMe has extended a data licensing collaboration with GSK for $20 million.
London stocks kick start Nov higher on upbeat earnings The internationally-focused FTSE 100 was up 0.3% at 8:10 GMT. GSK shares rose 1.2% after the drugmaker raised its full-year profit and sales forecasts. Shares of Next Plc gained 2.9% after raising its annual profit outlook for the fourth time in six months.
GSK 'firing on all cylinders' following bumper sales of new RSV vaccine Chief executive Emma Walmsley said it was ‘firing on all cylinders’ after launching the world’s first RSV jab in the US. Comments came as the company reported a 15 per cent jump in operating profit to £2.7billion for the third quarter. GSK shares fell 2.4 per cent, or 34.4p, to 1423p.
GSK lifts forecasts on strong vaccine launch GSK believes respiratory drug Arexvy could be its next big-selling medicine. It recorded third quarter sales of $862 million - far ahead of analyst forecasts.
GSK raises annual forecasts powered by strong Arexvy... GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year. The drugmaker is betting on Arexvy to be its next blockbuster medicine as it faces patent expiries.
GSK Boosts Profit Forecasts After ‘Outstanding’ RSV Vaccine Launch GSK shares rose on Wednesday after the pharma giant upgraded its profit guidance for the second time this year. The boost comes after the company said it expects sales for 2023 to rise between 12% to 13%. High demand for Arexvy has netted GSK around $850 million in sales during the third quarter.
FTSE 100 muted as strong earnings offset by losses in... FTSE 100 was flat at 9:01 GMT, while the mid-cap FTSE 250 moved 0.1% lower. GSK shares rose 1.2% after the drugmaker raised its full-year profit and sales forecasts for the second time this year. Top decliner automobiles and parts index fell 3.8% after Aston Martin lowered its 2023 volume outlook due to production issues for its new sports car DB12.
GSK raises annual forecasts again on strong Arexvy launch GSK raised its full-year profit and sales forecasts for the second time this year. The drugmaker is betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot.
ViiV Healthcare boss believes annual HIV jabs can replace daily tablets Deborah Waterhouse is chief executive of ViiV Healthcare, a specialist drugs firm under the control of UK pharma giant GSK. She says leading the HIV effort has always been her dream job.
GSK to pay $1 bln for exclusive license to J&J's... SK to pay $1 bln for exclusive license to J&J's hepatitis B therapy. JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018.
Pfizer RSV vaccine lags GSK´s as head-to-head... GSK accounts for close to two-thirds of RSV shots given in the U.S. since early September. The British drugmaker's early advantage may be tied to its positioning as the lone RSV shot offered by CVS Health. CVS is the nation's largest retail buyer of pharmaceuticals.
GSK says endometrial cancer drug meets overall survival... GSK says endometrial cancer drug meets overall survival goal in late-stage trial. Jemperli is currently approved in the United States and UK. It is the most common gynaecologic cancer in developed countries.
Sign Up
